Vincora Receives FDA Approval to Initiate U.S. Feasibility Study

Vincora, identified by PR Newswire as NeoChord, Inc. doing business as Vincora, has received FDA approval to initiate a U.S. early feasibility study of its transcatheter chordal repair system.

According to PR Newswire, Vincora is a medical technology company developing transcatheter therapies for mitral valve repair. The announced FDA action concerns the company’s plan to begin the stated early feasibility study in the United States.

FDA approval supports study initiation

PR Newswire reported that Vincora received FDA approval to initiate the U.S. early feasibility study. The study is focused on the company’s transcatheter chordal repair system.

The announcement identifies a regulatory-development milestone for the system: FDA approval to begin the specified study. PR Newswire’s report describes the action as approval to initiate the study, rather than an announcement of commercial availability.

Focus on mitral valve repair therapies

Vincora is developing transcatheter therapies for mitral valve repair, according to PR Newswire. Its announced study involves a transcatheter chordal repair system within that therapeutic focus.

The company’s identity is also noted in the announcement. PR Newswire identifies Vincora as NeoChord, Inc. doing business as Vincora.

Key details from the announcement

• Vincora received FDA approval, according to PR Newswire.
• The approval supports initiation of a U.S. early feasibility study.
• The study concerns a transcatheter chordal repair system.
• Vincora is developing transcatheter therapies for mitral valve repair.

For medical device sales professionals following structural heart and transcatheter therapy developments, the report establishes that Vincora has received FDA approval to initiate the named U.S. early feasibility study. PR Newswire published the announcement.